A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/7/2018
Start Date:March 6, 2017
End Date:January 2023
Contact:Eunice Aikins-Afful, JD
Email:AFT19@alliancefoundationtrials.org
Phone:617-525-8177

Use our guide to learn which trials are right for you!

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

This is a randomized, open-label, three-arm, phase 3 study in men with biochemically
recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.

Patients will be stratified by PSA doubling time (< 3 months vs. 3-9 months) and randomized
in 1:1:1 fashion to one of three treatment arms: (1) Control arm consisting of degarelix
monotherapy, (2) Experimental arm consisting of apalutamide in combination with degarelix,
and (3) Experimental arm consisting of apalutamide, abiraterone acetate + prednisone, and
degarelix. Patients will be treated for a maximum duration of 52 weeks and then enter follow
up phase until the time of PSA progression, development of metastasis, or patient withdrawal
from study, whichever occurs first. Patients with PSA progression will be followed long term
until the development of castration resistance, first metastasis, and death.

The primary endpoint of the study is PSA progression-free survival in the intent-to-treat
patient population. PSA progression during the 52-week treatment period is defined as a
rising PSA confirmed on repeat measurement, and at least 25% and 2 ng/mL above nadir or
baseline, whichever is lower. PSA progression during follow up defined as PSA > 0.2 ng/mL
confirmed by repeat measurement at least 2 weeks later. Secondary study endpoints include PSA
progression-free survival in testosterone-evaluable population, 36-month PSA progression-free
survival rate in both intent-to-treat and testosterone-evaluable populations, time to
testosterone recovery, time to castration resistance, metastasis-free survival, quality of
life, and safety. Each experimental arm will be compared against the control arm in pair-wise
fashion. The study is not powered to detect differences in primary or secondary endpoints
between the two experimental arms.

Inclusion Criteria:

- Histologically confirmed prostate adenocarcinoma

- Prior radical prostatectomy

- Biochemically recurrent prostate cancer with PSA doubling time ≤ 9 months at the time
of study entry. Calculation of PSA doubling time should include the use of all
available PSA values obtained within past 12 months prior to randomization, with a
minimum of 3 values separated by at least 2 weeks apart. PSA values obtained prior to
localized therapy will be excluded. PSA doubling time to be estimated using Memorial
Sloan Kettering Cancer Center online calculator
(https://www.mskcc.org/nomograms/prostate/psa-doubling-time)

- Prior adjuvant or salvage radiation or not a candidate for radiation based upon
clinical assessment of disease characteristics and patient co-morbidities.

- Screening PSA > 0.5 ng/mL

- No definitive evidence of metastases on screening CT or MRI of abdomen/pelvis and
radionuclide whole body bone scan per the judgment of the investigator. Abdominal
and/or pelvic lymph nodes measuring 2 cm or less in short axis diameter are allowed.
Lesions identified on other imaging modalities (e.g. PSMA or choline PET) that are not
visualized on CT and/or MRI or radionuclide bone scan are allowed. Equivocal lesions
on bone scan should be followed up with additional imaging as clinically indicated.

- Screening serum testosterone > 150 ng/dL

- Eastern Cooperative Oncology Group (ECOG) Performance Status grade 0 or 1

- Age ≥ 18 years

- Medications known to lower the seizure threshold (see Appendix 1) must be discontinued
or substituted at least 4 weeks prior to study entry.

- Agrees to use a condom (even men with vasectomies) and another effective method of
birth control if he is having sex with a woman of childbearing potential or agrees to
use a condom if he is having sex with a woman who is pregnant while on study drug and
for 3 months following the last dose of study drug. Must also agree not to donate
sperm during the study and for 3 months after receiving the last dose of study drug.

- Adequate organ function as defined by the following laboratory values at screening:

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase
[SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase
[SGPT]) < 2.5 x upper limit of normal (ULN)

- Total serum bilirubin ≤1.5 x ULN. In subjects with Gilbert's syndrome, if total
bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct
bilirubin is ≤1.5 × ULN, subject may be eligible)

- Serum potassium ≥ 3.5 mmol/L. Supplementation and re-screening is allowed.

- Estimated GFR > 45 ml/min using Cockroft-Gault equation

- Platelets ≥ 100,000/microliter independent of transfusion and/or growth factors
within 3 months prior to randomization

- Hemoglobin ≥ 9.0 g/dL independent of transfusion and/or growth factors within 3
months prior to randomization

- Serum albumin ≥ 3.0 g/dL

Exclusion Criteria:

- Prior androgen deprivation therapy and/or first generation anti-androgen (e.g.
bicalutamide, nilutamide, flutamide) for biochemically recurrent prostate cancer.
Prior ADT and/or first generation anti-androgen in the (neo)adjuvant and/or salvage
setting before, during, and/or following radiation or surgery is allowed provided last
effective dose of ADT and/or first-generation anti-androgen is > 9 months prior to
date of randomization and total duration of prior therapy is ≤ 36 months.

- Prior treatment with CYP17 inhibitor (e.g. ketoconazole, abiraterone acetate,
galeterone) or second generation androgen receptor antagonist including apalutamide or
enzalutamide

- Prior chemotherapy for prostate cancer except if administered in neoadjuvant or
adjuvant setting

- Use of 5-alpha reductase inhibitor within 42 days prior to randomization

- Use of investigational agent within 28 days prior to randomization

- Use of other prohibited medications within 7 days prior to cycle 1 day 1 on study
(Arms B and C only) (see Appendix 1 for list of prohibited medications)

- Prior bilateral orchiectomy

- Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within
1year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or
other benign CNS or meningeal disease which may require treatment with surgery or
radiation therapy)

- Uncontrolled hypertension

- Gastrointestinal disorder affecting absorption or the ability to swallow tablets

- Baseline severe hepatic impairment (Child-Pugh Class B & C)

- Intercurrent illness that is not controlled such as active infection, psychiatric
illness/social situations that would limit compliance with study requirements

- Any chronic medical condition requiring a higher dose of corticosteroid than
equivalent of 5 mg prednisone/prednisolone once daily
We found this trial at
44
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Concord, New Hampshire 03301
?
mi
from
Concord, NH
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Evanston, Illinois 60201
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fremont, California 94538
?
mi
from
Fremont, CA
Click here to add this to my saved trials
2615 East Clinton Avenue
Fresno, California 93703
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Hooksett, New Hampshire 03106
?
mi
from
Hooksett, NH
Click here to add this to my saved trials
Las Vegas, Nevada 89106
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lawton, Oklahoma 73505
?
mi
from
Lawton, OK
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
New York, New York 10025
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Quincy, Illinois 62301
?
mi
from
Quincy, IL
Click here to add this to my saved trials
?
mi
from
Saint Helena, CA
Click here to add this to my saved trials
Saint Louis Park, Minnesota 55416
?
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Scarborough, Maine 04074
?
mi
from
Scarborough, ME
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Toledo, Ohio 43623
?
mi
from
Toledo, OH
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
(202) 687-7695
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
?
mi
from
Washington,
Click here to add this to my saved trials
818 N. Emporia, #403
Wichita, Kansas 67214
(316) 262-4467
Cancer Center of Kansas The physicians of Cancer Center are hematologists and oncologists. The staff...
?
mi
from
Wichita, KS
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials